RT Journal Article
SR Electronic
T1 Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP ejhpharm-2020-002667
DO 10.1136/ejhpharm-2020-002667
A1 Christian Skalafouris
A1 Caroline Samer
A1 Jerome Stirnemann
A1 Olivier Grosgurin
A1 François Eggimann
A1 Damien Grauser
A1 Jean-Luc Reny
A1 Pascal Bonnabry
A1 Bertrand Guignard
YR 2021
UL http://ejhp.bmj.com/content/early/2021/04/07/ejhpharm-2020-002667.abstract
AB During Switzerland’s first wave of COVID-19, clinical pharmacy activities during medical rounds in Geneva University Hospitals were replaced by targeted remote interventions. We describe using the electronic PharmaCheck system to screen high-risk situations of adverse drug events (ADEs), particularly targeting prescriptions of lopinavir/ritonavir (LPVr) and hydroxychloroquine (HCQ) in the presence of contraindications or prescriptions outside institutional guidelines. Of 416 patients receiving LPVr and/or HCQ, 182 alerts were triggered for 164 (39.4%) patients. The main associated risk factors of ADEs were drug–drug interactions, QTc interval prolongation, electrolyte disorder and inadequate LPVr dosage. Therapeutic optimisation recommended by a pharmacist or proposals for additional monitoring were accepted in 80% (n=36) of cases. Combined with pharmacist contextualisation to the clinical context, PharmaCheck made it possible to successfully adapt clinical pharmacist activities by switching from a global to a targeted analysis mode in an emergency context.All data relevant to the study are included in the article or uploaded as supplementary information.